Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Peptide Half-Life Visualiser

Pick a peptide and see its first-order plasma decay curve. Only peptides whose monograph quotes a half-life from a named source (a PubMed record, a DailyMed label, a trial registration or a DOI) are plotted, and the source is linked under the curve.

Educational only. Not a personalised PK model. Not for planning administration.

GHRP-2 — as written on its monograph: “0.55 hours (about 33 minutes) after a single intravenous dose in children; no adult or subcutaneous figure found”. Plotted at 33 min. The curve shows first-order elimination over 5 half-lives (≈2.8 h).

Source: PubMed 9543135
Quoted from the source
GHRP-2 PK parameters (mean +/- SD) were: alpha = 13.4 +/- 9.7 h(-1), beta = 1.3 +/- 0.3 h(-1), t(1/2beta) = 0.55 +/- 0.14 h,
0%25%50%75%100%1× t½2× t½3× t½4× t½5× t½

First-order plasma decay is a simplification. Real peptide PK can be multi-compartmental and dose-dependent (saturation, receptor binding, slow-absorption formulations). This visualiser is for interpreting reported half-lives in published sources, not for predicting individual PK.

Sourced, but not plotted

These monographs name a source for their half-life, but the value cannot be drawn as one curve without guessing.

  • BPC-157 (“Under 30 minutes in rats and beagle dogs. A 2026 review says a two-person human pilot also showed under 30 minutes; the pilot's own stated methods are blood work and vital signs”): not plotted because it gives a bound (less than, up to, at least), not a half-life. PubMed 36588717
  • Cagrilintide (“6.6 to 8.1 days (159 to 195 hours) in a phase 1b trial in adults with overweight or obesity, measured with semaglutide given alongside”): not plotted because it has a number that is not attached to a unit of time. PubMed 33894838
  • Kisspeptin-10 (“3.8 minutes in men and 4.1 minutes in women (follicular and preovulatory phases), measured as immunoreactive kisspeptin after an intravenous infusion (Jayasena 2011)”): not plotted because it has a number that is not attached to a unit of time. PubMed 21976724
  • PT-141 (“About 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous dose (Vyleesi label)”): not plotted because it states more than one half-life (2.7 hours; 1.9 to 4.0 hours). DailyMed label
  • Retatrutide (“About 6 days (phase 1b trial in people with type 2 diabetes)”): not plotted because it has a number that is not attached to a unit of time. PubMed 36354040
  • Tesamorelin (“26 minutes in healthy subjects and 38 in HIV-infected patients (original 2010 Egrifta label); 8 minutes (Egrifta SV label, 2026); 11 minutes (Egrifta WR label, 2026)”): not plotted because it has a number that is not attached to a unit of time. DailyMed label
  • Thymosin α-1 (“Less than 3 hours (elimination half-life after subcutaneous injection in nine healthy volunteers)”): not plotted because it gives a bound (less than, up to, at least), not a half-life. PubMed 10027483
  • Tirzepatide (“About 5 days (Mounjaro label); 5 to 6 days in people with overweight or obesity (Zepbound label)”): not plotted because it states more than one half-life (5 days; 5 to 6 days). DailyMed label

No human half-life in a source we checked

These monographs either state no half-life or state one without a source. The tool does not plot them.

What the curve does and doesn’t model

The plotted curve is first-order plasma decay: concentration halves every t½ interval, and after five half-lives it’s under 4% of the peak. Reading the curve tells you roughly how quickly a compound leaves plasma.

It does not model:

  • Multi-compartment pharmacokinetics — many drugs show a rapid distribution phase followed by a slower elimination phase, and a single half-life can hide the second.
  • Tissue retention — a compound can be cleared from tissue at a different rate from plasma.
  • Saturation — receptor binding, protein binding and enzyme saturation can make the relationship between dose and concentration nonlinear.
  • Slow-absorption formulations — a product designed for slow absorption or albumin binding gives a plasma profile unlike a simple decay curve.
  • Route of administration — a half-life measured by one route may not apply to another.

Where the numbers come from

Each plotted value is the half-life written on the peptide’s monograph, and it is plotted only if the monograph names a source for it and the passage quoted from that source contains the same numbers. The source link and the quoted passage are shown under the curve. A range is plotted at its midpoint, with both ends drawn faintly. A string that states more than one half-life, gives only a bound, or has no number with a unit of time is not plotted. If a half-life on the curve looks wrong, the fix goes in the peptide’s frontmatter, not here.